Products
BioEngine has developed nearly 100 types of serum-free media for different cell lines, which are suitable for antibodies, vaccines and cell and gene therapy (CGT) fields.
Time:Feb 01,2021
Recently, after strict examination and announcement by Pudong New Area Science and Economy Commission, BioEngine has been recognized as the "2020 Pudong New Area Enterprise R&D Institution" based on its scientific and technological innovation capability and R&D strength, and has received authoritative recognition from government departments.
BioEngine has been cultivating in the field of animal cell mass culture technology for many years. Since its establishment, BioEngine has always been innovation-driven, technology-led, and service-driven, promoting the transformation of scientific and technological innovation results with its own technological advantages, and continuously providing development momentum for the biomedical industry. In the future, BioEngine will continue to attach great importance to the development of R&D and innovation capabilities, increase investment in scientific research and development capabilities, further optimize the construction of the R&D system, continue to enhance the core competitiveness of the enterprise, and bring more value to the industry.
We have a professional technical team to provide high quality one-stop cell culture service from process development
and optimization, medium formulation design to medium processing and manufacturing for all biopharmaceutical companies.
If you have any question, please click "Quick Message" and leave your message, we will reply to you as soon as possible.
If anything urgent, please call (86)21-68582660-2792.
3F&4F, Building 3, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai, PRC